Comparative Pharmacology
Head-to-head clinical analysis: PRANDIMET versus QTERN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRANDIMET versus QTERN.
PRANDIMET vs QTERN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PRANDIMET combines repaglinide (a meglitinide analog) and metformin (a biguanide). Repaglinide lowers blood glucose by stimulating insulin release from pancreatic beta cells via closure of ATP-sensitive potassium channels, leading to calcium influx and exocytosis of insulin. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
QTERN is a fixed-dose combination of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Dapagliflozin reduces renal glucose reabsorption, increasing urinary glucose excretion. Saxagliptin increases incretin hormones, enhancing insulin secretion and decreasing glucagon levels.
Initial dose: 1.25 mg repaglinide/250 mg metformin orally twice daily with meals. Maximum dose: 10 mg repaglinide/2500 mg metformin per day.
One tablet orally twice daily; each tablet contains dapagliflozin 10 mg and saxagliptin 5 mg.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours. Clinically, repaglinide has a short half-life, allowing for flexible dosing immediately before meals.
Terminal half-life approximately 5 hours; supports twice-daily dosing.
Renal: ~90% (60% as repaglinide metabolites, 30% as unchanged repaglinide); Biliary/fecal: ~8%
Fecal (59% unchanged) and renal (42% unchanged, primarily via tubular secretion).
Category C
Category C
Antidiabetic Combination
Antidiabetic Combination